Association between bile area in the duodenal bulb and abdominal symptoms: Quantitative analysis using blue laser imaging

DAIKI ABE1, TSUTOMU TAKEDA1, DAISUKE ASAOKA2, TOMOYO IWANO1, RYOTA UCHIDA1, HISANORI UTSUNOMIYA1, SHOTARO OKI1, NOBUYUKI SUZUKI1, ATSUSHI IKEDA1, NOBORU YATAGAI1, YOICHI AKAZAWA1, KOHEI MATSUMOTO1, KUMIKO UEDA1, HIROYA UEMAYA1, MARIKO HOJO1, YUKO KOJIMA3, SHINJI NAKAMURA3, SHUKO NOJIRI4 and AKIHITO NAGAHARA1

1Department of Gastroenterology, Juntendo University School of Medicine, Tokyo 113-8421;
2Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo 136-0075,
3Laboratory of Morphology and Image Analysis, Biomedical Research Core Facilities;
4Department of Medical Technology Innovation Center, Juntendo University School of Medicine,
Tokyo 113-8421, Japan

Received June 10, 2022; Accepted August 8, 2022

DOI: 10.3892/br.2022.1566

Abstract. Bile acids are strongly associated with the pathogenesis of functional gastrointestinal diseases. In recent years, blue laser imaging (BLI) endoscopy has emerged as a novel image-enhanced endoscopic method, which illustrates bile as a reddish hue. The present study investigated the factors that affect the area of bile in duodenal bulbs using BLI. For this purpose, patients (356 cases) who underwent upper endoscopy with BLI between April, 2017 and December, 2019, and completed patient background and symptom questionnaires [Constipation Scoring System (CSS), Bristol Stool Form Scale (BSFS) and Frequency Scale for Symptoms of gastroesophageal reflux disease (FSSG)], were retrospectively investigated. Each BLI bile score was calculated as a percentage of bile area in a field of view in the duodenal bulb using a KS400 image analysis system, and the association with abdominal symptoms was examined using multiple regression analysis. The patient characteristics included the following: Age (in years), 69.9±11.3; male/female ratio, 146/210; body mass index, 23.0±3.8; reflux esophagitis (M/A/B/C), 143/19/3/3; atrophic gastritis (C-0/C1-3/O1-3), 132/100/124; proton pump inhibitor potassium competitive acid blocker/aspirin/ursodeoxycholic acid/gall bladder stones/cholecystectomy, 105/27/18/43/18; BLI bile score, 7.10 (±14.34); CSS score, 3.55 (±3.80); BSFS score, 3.91 (±1.02); and FSSG score, 4.80 (±5.76). Correlation coefficients (P<0.05) for the BLI bile score were found for cholecystectomy (Rho=0.137) and aspirin use (Rho=0.118). In multiple regression analysis, independent predictors of the BLI bile score were cholecystectomy [standardized partial regression coefficient (β)=0.169, P=0.001] and the BSFS score (β=0.107, P=0.042). On the whole, the present study demonstrates that the duodenal bile area in BLI upper endoscopy is associated with cholecystectomy and fecal characteristics.

Introduction

Functional gastrointestinal diseases (FGIDs) are syndromes in which no organic disease is evident, despite the presence of abdominal symptoms. A number of comorbidities exist, such as functional dyspepsia, functional constipation (FC), gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS), with a multi-national study using an internet survey suggesting an extremely high incidence of 40.3% (1). FC is one of the most common digestive disorders, and its incidence seems to increase with advancing age (2). In Japan, an internet survey reported that 28.4% of respondents considered themselves to commonly be constipated (3). Chronic constipation greatly impairs the quality of life (QOL) of patients (4). Tanabe et al (5) reported that the QOL of patients was reduced in the constipation group, with the Bristol Stool Form Scale (BSFS) score being significantly lower than that of the control group, indicating harder stools in the former. In addition, IBS is a chronic functional disease characterized by abdominal pain, abnormal bowel movements and changes in stool shape; its economic loss due to an impaired QOL cannot be ignored (6). Therefore, measures with which to combat FGIDs have become an important issue.

Bile acids are strongly associated with the pathogenesis of FGIDs, and new mechanisms involving these have recently been reported in IBS, chronic diarrhea, and FC (7). In recent years, inhibitors of bile acid transporters (8,9) have been launched as new laxative agents, and the effects of bile on the intestinal tract have attracted considerable attention (10,11).

Correspondence to: Dr Tsutomu Takeda, Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
E-mail: t-takeda@juntendo.ac.jp

Key words: abdominal symptoms, bile, blue laser imaging, Bristol Stool Form Scale, duodenum
Blue laser imaging (BLI) has emerged as a novel system for image-enhanced endoscopy using laser light; bile presents with a reddish tone in narrow band imaging (12-14), improving its visibility. Linked color imaging also enhances color tone and improves visibility, although the contrast in the color tone of bile from that of the background mucosa is not noticeable. Thus, a difference in color tone is more apparent when BLI is used. The association between duodenal bile area and abdominal symptoms, fecal characteristics, and constipation remains unclear. Thus, the present study investigated the factors that affect bile area in the duodenal bulb using BLI.

Patients and methods

Study design. The present study was a retrospective cross-sectional study conducted between April, 2017 and December, 2019 at a single-center university hospital (Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan) to explore the association between bile area in the duodenal bulb and abdominal symptoms. An EG-L590WR, EG-L600WR7 or EG-L600ZW7 (FUJIFILM Wako Pure Chemical Corporation) endoscope system, AdvanciaHD VP-4450HD or LASEREO7000 VP-7000 (FUJIFILM Wako Pure Chemical Corporation; Structure Emphasis: B6, Color Emphasis: C1) video processor, and LASEREO LL-4450 or LASEREO7000 LL-7000 (FUJIFILM Wako Pure Chemical Corporation) light source were used. Patients fasted for at least 12 h prior to the esophagogastroduodenoscopy (EGD), which was performed in the morning. Pre-treatment consisted of the oral administration of 80 ml of 2% dimethicone solution, diluted two-fold with water as an antifoam agent to remove mucus, and pharyngeal anesthesia with an 8% lidocaine pump spray. After examining the esophagus, the endoscope was inserted into the stomach; the duodenum was examined prior to examining the stomach. When the scope was inserted into the duodenum, a reddish tinted area of the bulb was defined as bile by BLI observation without a suction operation. Images were recorded close to duodenal bulb air insufflation. In addition, patients were excluded if bubbles, mucus and halation were not clearly observed in the duodenal bulb. For the quantitative analysis of bile, each BLI bile score was calculated as the percentage of bile area in a field of view of the duodenal bulb using a KS400 image analysis system (Carl Zeiss Imaging Solutions GmbH). The association with each factor, including fecal characteristics, and abdominal and constipation symptoms, was retrospectively examined using multiple regression analysis. Patients provided written informed consent before undergoing the EGD.

Inclusion criteria. Patients were included if all of the following information was available from their medical records: i) Patient characteristics [sex, age, body mass index (BMI)]; ii) Helicobacter pylori (H. pylori) infection status (negative, positive, or negative after eradication); iii) treatment with a proton pump inhibitor (PPI)/potassium competitive acid blocker (PCAB), ursooxycholic acid (UDCA), aspirin, laxative/exercise promotion (prokinetics); iv) a history of cholecystectomy and gallbladder (GB) stones; v) EGD results [Barrett's esophagus and endoscopic gastric mucosal atrophy score (EGAS), reflux esophagitis (RE)]; vi) constipation questionnaire [constipation scoring system (CSS)]; vii) stool shape questionnaire BSFS); viii) upper abdominal symptom questionnaire [frequency scale for symptoms of GERD (FSSG)].

Exclusion criteria. Patients with a history of acute cerebrovascular, gastrointestinal, renal, coronary, hepatic, or respiratory events were excluded from the study. Patients were excluded if they were found to have the following conditions: A history of gastrointestinal surgery, inflammatory bowel disease, advanced gastrointestinal cancer, erosive duodenitis, active gastric or duodenal ulcer, deformity due to duodenal scars, malignant lymphoma, leukemia, multiple myeloma, or mental illness. Patients who did not have a colonoscopy and who were taking laxatives were excluded from the study.

Assessments. The BMI was calculated by dividing body weight by body height in m² (kg/m²). A positive result in a 13C-urea breath test and/or the presence of specific serum antibodies was defined as positive for H. pylori infection. A negative result for H. pylori infection 4 to 8 weeks after the end of eradication therapy was defined as being successful. Daily use of any of the five types of PPIs/PCABs (rabeprazole, lansoprazole, omeprazole, esomeprazole or vonoprazan) for >8 weeks was regarded as indicating a PPI/PCAB user. Patients taking a normal dose of aspirin or a PPI/PCAB were regarded as users of such therapies.

EGD findings. With regard to the EGD results, patients were identified as having RE of grade A, B, C, or D using the partially revised Los Angeles (LA) classification system (15). Non-erosive reflux esophagitis was classified based on a modified LA classification system (16). As regards Barrett's esophagus, Ultrashort-segment Barrett's esophagus (USBE) was defined as the maximum length of the cylindrical epithelium <1 cm. Long-segment Barrett's esophagus (LSBE) was defined as a circumferential cylindrical epithelium >3 cm in length. Short-segment Barrett's esophagus (SSBE) was defined as Barrett's esophagus of intermediate length between USBE and LSBE according to the Prague C&M criteria (17). The Kimura-Takemoto classification system was used to classify endoscopic gastric mucosal atrophy as C-0 (normal), C-1, C-2, C-3, O-1, O-2 or O-3 (18), in line with the location of the endoscopic atrophic border. An EGAS value was assigned to each patient depending on atrophy: 0=C-0 type, 1=C-1 type, 2=C-2 type, 3=C-3 type, 4=O-1 type, 5=O-2 type or 6=O-3 type. The mean EGAS in each group was calculated.

Questionnaire about constipation severity. The CSS questionnaire was self-administered and evaluated the severity of constipation. This had previously been validated for evaluating constipation in a clinical trial setting (19). The CSS questionnaire is comprised of eight items outlining the symptoms of constipation as follows: Painful evacuation, frequency of bowel movements, abdominal pain, incomplete evacuation, assistance with evacuation, length of time per attempt, duration of constipation and unsuccessful attempts at evacuation per 24 h. Each item was scored between 0 and 4 apart from ‘assistance for evacuation’, for which the score was from 0 to 2. The overall score for the CSS questionnaire was between 0 and 30, with the higher the score the worse the constipation symptoms.
Questionnaire about stool shape. A BSFS (20) was used to assess and classify stool shape and consistency into seven categories as follows: i) Separate hard lumps similar to nuts; ii) sausage-shaped but lumpy; iii) similar to a sausage or snake but with cracks on the surface; iv) similar to a sausage or snake, smooth and soft; v) soft blobs with clear cut edges; vi) fluffy pieces with ragged edges, a mushy stool; and vii) watery, no solid pieces.

Ethics. The present study was approved by the Juntendo Tokyo Koto Geriatric Medical Center Ethics Committee (protocol no. 106-8) and was performed according to the tenets of the Declaration of Helsinki. The Juntendo Tokyo Koto Geriatric

| Characteristic   | Value                  |
|------------------|------------------------|
| Age in years, mean ± SD (range) | 69.9±11.3 (27-91) |
| Sex (male:female) | 146:210                |
| BMI (kg/m²)      | 23.0±3.8               |
| Reflux esophagitis | None, n=188; grade M, n=143; grade A, n=19; grade B, n=3; grade C, n=3; grade D, n=0 |
| Barrett's esophagus | None, n=292; USBE, n=42; SSBE, n=22; LSBE, n=0 |
| H. pylori        | Negative, n=212; positive, n=79; post-eradication, n=65 |
| Atrophic gastritis | C-0, n=132; C-1-3, n=100; O-1-3, n=124 |
| PPI/PCAB         | Non-users, n=251; users, n=105 |
| Aspirin          | Non-users, n=329; users, n=27 |
| UDCA             | Non-users, n=338; users, n=18 |
| GB stones        | None, n=313; present, n=43 |
| Cholecystectomy  | None, n=338; performed, n=18 |

BMI, body mass index; GB stones, gallbladder stones; H. pylori, Helicobacter pylori; LSBE, long-segment Barrett’s esophagus; PPI: proton pump inhibitor/PCAB: potassium-competitive acid blocker; SD, standard deviation; SSBE, short-segment Barrett’s esophagus; USBE, ultrashort-segment Barrett’s esophagus; UDCA, ursodeoxycholic acid.

Table I. Clinical characteristics of the patients in the present study (n=356).

| Characteristics   | Value                                  |
|-------------------|----------------------------------------|
| BLI bile score    | 7.10±14.34 (0-85.3)                    |
| CSS               | 3.55±3.80 (0-22)                       |
| BSFS              | 3.91±1.02 (1-7)                        |
| FSSG              | 4.80±5.76 (0-37)                       |

Data are presented as the mean ± standard deviation (range). BLI, blue laser imaging; BSFS, Bristol Stool Form Scale; CSS, constipation scoring system; FSSG, frequency scale for the symptoms of GERD; GERD, gastroesophageal reflux disease.

Table II. BLI bile score and symptom questionnaire scores of study patients (n=356).

Medical Center Ethics Committee determined that the present study was exempt from the need to obtain informed consent from patients. Also, in accordance with the same ethics committee, information on the study for patients was available on our hospital’s homepage and patients were guaranteed the opportunity to change their mind about participating.

Statistical analyses. Correlations between the BLI bile score, assuming bile area value, and various clinical parameters (sex, age, BMI, reflux esophagitis, Barrett's esophagus, atrophic gastritis, H. pylori infection status, PPI/PCAB use, aspirin use, UDCA use, a history of GB stones, a history of cholecystectomy, and CSS BSFS, and FSSG scores) were determined using Spearman's correlation coefficient. Data for age, BMI, and CSS, BSFS and FSSG scores are presented as the mean ± standard deviation. For multiple regression analysis, the BLI bile score was used as the dependent variable, and age, sex, BMI, reflux esophagitis, Barrett's esophagus, atrophic gastritis, H. pylori infection status, PPI/PCAB use, aspirin
use, UDCA use, a history of GB stones and a history of cholecystectomy were deemed independent variables. Since the BLI score did not exhibit a normal distribution (as shown by the Kolmogorov-Smirnov test), the score was analyzed by adding 1 to the score during correlation and multiple regression analyses, followed by logarithmic transformation. Multiple regression analyses of risk factors for the BLI bile score were performed by a stepwise method and multicollinearity was determined by a variance inflation factor of 10 or greater. All statistical analyses were performed using SPSS for Windows, version 28.0 (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical characteristics of the patients in the study. A flow chart of the study participants is presented in Fig. 1. The clinical characteristics of the study participants are listed in Table I. The mean age of the participants was 69.9 years (range, 27-91 years). Of the 356 participants, 146 were male and 210 were female; the mean BMI was 23.0. Reflux esophagitis was found in 47.2% of the participants, according to the Prague C&M criteria (17), as follows: USBE (maximum extent <1 cm), 11.8%; SSBE (maximum extent ≥1 cm, circumferential extent <3 cm), 6.2% were predominantly present; and LSBE (circumferential extent ≥3 cm) was absent. In total, 79 participants were found to have H. pylori infection, and 212 patients negative for this infection and 65 post-eradication. Atrophic

Table III. Correlation between the BLI bile score and various clinical parameters.

| Clinical parameters     | Rho  | P-value |
|------------------------|------|---------|
| Age                    | 0.094| 0.075   |
| Sex                    | 0.000| 0.999   |
| BMI                    | -0.010| 0.848  |
| Reflux esophagitis     | 0.015| 0.773   |
| Barrett's esophagus    | -0.059| 0.268  |
| H. pylori              | 0.038| 0.478   |
| Atrophic gastritis     | 0.014| 0.786   |
| PPI/PCAB               | 0.091| 0.087   |
| Aspirin                | 0.118| 0.026   |
| UDCA                   | 0.003| 0.949   |
| GB stones              | 0.063| 0.237   |
| Cholecystectomy        | 0.137| 0.010   |
| CSS                    | -0.030| 0.570  |
| BSFS                   | 0.029| 0.589   |
| FSSG                   | -0.017| 0.749  |

BMI, body mass index; BSFS, Bristol Stool Form Scale; CSS, constipation scoring system; FSSG, frequency scale for symptoms of GERD; GERD, gastroesophageal reflux disease; GB stones, gallbladder stones; H. pylori, Helicobacter pylori; PPI, proton pump inhibitor; PCAB, potassium-competitive acid blocker; rho, Spearman’s correlation coefficient; UDCA, ursodeoxycholic acid.
Figure 3. Endoscopic findings of duodenal mucosa of bulbs with bile. (A) White light imaging illustrating bile in the bulb of the duodenum. (B) Linked color illustrating bile as a light green color in the bulb of the duodenum, although this is obscure compared to BLI. (C) BLI clearly illustrating bile as a red color in the bulb of the duodenum. (D) KS400: The BLI bile score was 22.35 in the bulb of the duodenum. BLI, blue laser imaging.

Figure 4. Endoscopic findings of duodenal mucosa of bulbs showing a large area of bile. (A) White light imaging illustrating bile in the bulb of the duodenum. (B) Linked color imaging illustrating bile as a light green color in the bulb of the duodenum, although this is obscure compared to BLI. (C) BLI very clearly illustrating a large area of bile as a red color in the bulb of the duodenum. (D) KS400: The BLI bile score was 61.60 in the bulb of the duodenum. BLI, blue laser imaging.
Bile has long been described as a factor affecting fecal characteristics in the liver. The majority of these are reabsorbed from the intestinal tract and reused by the liver (21,22). The main roles of bile acids include the regulation of cholesterol in the body, and the digestion and absorption of lipids in the small intestine (23). In addition, bile acids that are not reabsorbed flow into the large intestine to promote gastrointestinal motility and water secretion in the lumen of the large intestine. Bile acids also increase sensitivity to rectal-stretching stimuli, which are said to promote bowel movements (24-26). Bile acid transporter inhibitors are drugs that utilize these effects (8,9). Furthermore, in individuals with IBS and constipation, bile acid synthesis is decreased on an empty stomach compared to healthy individuals (27). The administration of chenodeoxycholic acid increases the frequency of defecation and the BSFS score (28). However, a high level of bile acids is a contributing factor to diarrhea, which is predominant in IBS (29). If the amount of bile acids flowing into the large intestine is physiologically high, this may have an effect on fecal characteristics and constipation symptoms. This may be related to the results of the significantly higher value for the BSFS score in patients demonstrating a large area of bile (high BLI bile score) in the present study.

In addition to fecal characteristics, in the present study, a significant difference was also found with a history of cholecystectomy as a factor affecting bile area. A previous study reported an increased incidence of diarrhea following cholecystectomy (30). Post-cholecystectomy diarrhea (PCD) (31) is part of post-cholecystectomy syndrome (PCS), which is difficult to treat. It has been shown that ~12 to 35.6% of patients with PCS suffer from chronic diarrhea to varying degrees (32-36). The occurrence of PCD is considered to be related to changes in the bile flowing into the intestine following a cholecystectomy (37), and bile acid malabsorption is considered to be a contributing factor (38). It has also been suggested that in patients with dyspepsia who have undergone cholecystectomy, a marked increase occurs in duodenogastric bile reflux on an empty stomach and continued bile excretion from the common bile duct (39), inferring that these mechanisms increased bile volume into the duodenal bulb in such patients. Although Barrett’s esophagus and upper abdominal symptoms were not associated with bile area in the present study, a causal association is unclear as bile reflux into the stomach was not assessed. No association between the BLI bile score and FSSG score has been found; however, chronic reflux of bile into the stomach and esophagus may induce symptoms (40-42); thus, further studies, such as the analysis of bile volume in the stomach and esophageal pH monitoring tests, are considered necessary.

Table IV. Association between the BLI bile score and other variables in multiple regression analysis.

| Variables          | B     | SE    | 95% CI of B | β     | t     | VIF  | P-value |
|--------------------|-------|-------|-------------|-------|-------|------|---------|
| Cholecystectomy    | 0.974 | 0.300 | 0.383, 1.565| 0.169 | 3.241 | 1.001| 0.001   |
| BSFS               | 0.132 | 0.064 | 0.005, 0.258| 0.107 | 2.045 | 1.001| 0.042   |

B, partial regression coefficient; BLI, blue laser imaging; BSFS, Bristol Stool Form Scale; CI, confidence interval; SE, standard error; t, t-ratio; VIF, variance inflation factor; B, standardized partial regression coefficient.

Discussion

To the best of our knowledge, no previous study has yet examined the association between duodenal bile area, fecal characteristics and constipation symptoms. The present study focused on the bile area in the duodenum (bile area was analyzed as a BLI bile score) using EGD and examined its association with background factors, abdominal symptom scores and fecal characteristic scores. If was found that independent predictors of the BLI bile score were cholecystectomy and a high BSFS score. To the best of our knowledge, the present study is the first to quantitatively analyze the bile area in the duodenal bulb using EGD and to demonstrate a positive association with fecal characteristics (soft) and after a cholecystectomy.

Bile has long been described as a factor affecting fecal characteristics and constipation symptoms. Bile acids, the main component of bile, are biosynthesized from cholesterol in the liver. The majority of these are reabsorbed from the intestinal tract and reused by the liver (21,22). The main roles of bile acids include the regulation of cholesterol in the body, and the digestion and absorption of lipids in the small intestine (23). In addition, bile acids that are not reabsorbed flow into the large intestine to promote gastrointestinal motility and water secretion in the lumen of the large intestine. Bile acids also increase sensitivity to rectal-stretching stimuli, which are said to promote bowel movements (24-26). Bile acid transporter inhibitors are drugs that utilize these effects (8,9). Furthermore, in individuals with IBS and constipation, bile acid synthesis is decreased on an empty stomach compared to healthy individuals (27). The administration of chenodeoxycholic acid increases the frequency of defecation and the BSFS score (28). However, a high level of bile acids is a contributing factor to diarrhea, which is predominant in IBS (29). If the amount of bile acids flowing into the large intestine is physiologically high, this may have an effect on fecal characteristics and constipation symptoms. This may be related to the results of the significantly higher value for the BSFS score in patients demonstrating a large area of bile (high BLI bile score) in the present study.

In addition to fecal characteristics, in the present study, a significant difference was also found with a history of cholecystectomy as a factor affecting bile area. A previous study reported an increased incidence of diarrhea following cholecystectomy (30). Post-cholecystectomy diarrhea (PCD) (31) is part of post-cholecystectomy syndrome (PCS), which is difficult to treat. It has been shown that ~12 to 35.6% of patients with PCS suffer from chronic diarrhea to varying degrees (32-36). The occurrence of PCD is considered to be related to changes in the bile flowing into the intestine following a cholecystectomy (37), and bile acid malabsorption is considered to be a contributing factor (38). It has also been suggested that in patients with dyspepsia who have undergone cholecystectomy, a marked increase occurs in duodenogastric bile reflux on an empty stomach and continued bile excretion from the common bile duct (39), inferring that these mechanisms increased bile volume into the duodenal bulb in such patients. Although Barrett’s esophagus and upper abdominal symptoms were not associated with bile area in the present study, a causal association is unclear as bile reflux into the stomach was not assessed. No association between the BLI bile score and FSSG score has been found; however, chronic reflux of bile into the stomach and esophagus may induce symptoms (40-42); thus, further studies, such as the analysis of bile volume in the stomach and esophageal pH monitoring tests, are considered necessary.
While reports exist on the association between bile and fecal characteristics, and constipation and diarrhea symptoms after cholecystectomy, the application of endoscopy to the prediction and diagnosis of these remains undescribed. The findings of the present study suggest that bile area in the duodenal bulb reflects the pathophysiology of diarrhea and its observation in EGD is expected to lead to the development of a novel approach to the diagnosis and treatment of diarrhea.

However, the present study has several limitations. First, as the study was retrospective and had a single-center, hospital-based design, a causal association between bile area, and constipation and fecal characteristics could not be established. Second, the authors were not able to collect bile and analyze bile acids, bile volume, the amount of gastric juice and their various other components. In addition, the present study did not confirm the reproducibility of the BLI bile score in the same patients. The evaluation was performed only in the duodenal bulb and not in the descending part or deeper into the duodenum due to the difficulty in quantitatively analyzing the bile volume in these areas; the evaluation was performed only in the flat duodenal bulb. Additionally, the results of the present study should only be considered preliminary, since a relatively small cohort was used and the backgrounds of the participants were not extensively investigated, including smoking history, alcohol consumption, diet, exercise habits, work, marital status, education and the use of medications apart from PPIs, laxatives, aspirin and prokinetics. Therefore, the data obtained herein may not be generalizable to everyone in a population.

In conclusion, the present study, which was a hospital-based, cross-sectional study, found a positive association between bile area in the duodenal bulb and fecal characteristics. In the future, the examination and diagnosis of fecal characteristics may be aided by EGD. Such associations and their biological mechanisms require further investigation.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The present study was performed according to the Declaration of Helsinki. The Juntendo Tokyo Koto Geriatric Medical Center Ethics Committee approved the study and protocol (protocol no. 106–8). The Juntendo Tokyo Koto Geriatric Medical Center Ethics Committee determined that this study was exempt from the need to obtain informed consent from patients. Study participants were provided with information about the study on the homepage of the hospital, as well as the opportunity to opt out of the study in accordance with directions by the same ethics committee.

Competing interests
The authors declare that they have no competing interests.

References
1. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, et al: Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study. Gastroenterology 160: 99-114.e3, 2021.
2. Higgins PD and Johanson JF: Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 99: 750-759, 2004.
3. Tamura A, Tomita T, Oshima T, Toyoshima F, Yasamaki T, Okugawa T, Kondo T, Kono T, Tozawa K, Ikehara H, et al: Prevalence and self-recognition of chronic constipation: Results of an internet survey. J Neurogastroenterol Motil 22: 677-685, 2016.
4. Wald A, Scarpignato C, Kamman MA, Mueller-Lissner S, Helfrich I, Schuitt C, Bubeck J, Limoni C and Petreni O: The burden of constipation on quality of life: Results of a multinational survey. Aliment Pharmacol Ther 26: 227-236, 2007.
5. Tanabe A, Adachi K, Yamaguchi Y, Izawa S, Yamamoto S, Hijkata Y, Ebi M, Funaki Y, Ogasawara N, Goto C, et al: Gut environment and dietary habits in healthy Japanese adults and their association with bowel movement. Digestion 101: 706-716, 2020.
6. Canavan C, West J and Carol T: Review article: The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 40: 1023-1034, 2014.
7. Appleby RN and Walters JR: The role of bile acids in functional GI disorders. Neurogastroenterol Motil 26: 1057-1069, 2014.
8. Nakajima A, Seki M and Taniguchi S: Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: A phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol 55: 525-534, 2018.
9. Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP and Camilleri M: Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase-3 trial and an open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 3: 537-547, 2018.
10. Beeckmans D, Farré R, Riethoven D, Keita ÄV, Augustijns P, Söderholm JD, Vanuytsel T, Vanheel H and Tack J: Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. Neurogastroenterol Motil 32: e13788, 2022.
11. Wauters L, Ceulemans M, Lambaerts M, Accarrie A, Toth J, Mols R, Augustijns P, Tack J and Vanuytsel T: Association between duodenal bile salts and gastric emptying in patients with functional dyspepsia. Gut 70: 2208-2210, 2021.
12. Choi HH, Moon JH and Lee YN. Advanced imaging technology in biliary tract diseases: Narrow-band imaging of the bile duct. Clin Endosc 48: 498-502, 2015.
13. Moon JH, Terheggen G, Choi HJ and Neuhaus H: Peroral cholangioscopy: Diagnostic and therapeutic applications. Gastroenterology 144: 276-282, 2013.

14. Itoi T, Sofani A, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Moriyasu F and Gotoda T: Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 66: 730-736, 2007.

15. Armstrong D, Bennett JR, Blum AL, Dent J, De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, et al: The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 111: 85-92, 1996.

16. Hongo M: Minimal changes in reflux esophagitis: Red ones and white ones. J Gastroenterol 41: 95-99, 2006.

17. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GN and Vieth M: The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 131: 1392-1399, 2006.

18. Kimura K and Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1: 87-97, 1969.

19. Agachan F, Chen T, Pfeifer J, Reissman P and Wexner SD: A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 39: 681-685, 1996.

20. Lewis SJ and Heaton KW: Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32: 920-924, 1997.

21. Chiang JY: Bile acid metabolism and signaling. Compr Physiol 3: 1191-1212, 2013.

22. Chiang JY and Ferrell JM: Bile acid metabolism in liver pathology. Gene Expr 18: 71-87, 2018.

23. Di Ciula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ and Portincasa P: Bile acid physiology. J Hepatol 53 (Suppl 1: S3-S105): S4-S14, 2017.

24. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ and Cook LJ: The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol 282: G443-G449, 2002.

25. Hofmann AF: The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159: 2647-2658, 1999.

26. Edwards CA, Brown S, Baxter AJ, Bannister J3 and Read NW: Effect of bile acid on anorectal function in man. Gut 30: 383-386, 1989.

27. Shin A, Camilleri M, Vijayavargiya P, Bucsiglio I, Burton D, Ryks M, Rhoten D, Lukee A, Saenger A, Girtman A and Zinsmeister AR: Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 11: 1270-1275.e1, 2013.

28. Rao AS, Wong BS, Camilleri M, Odunsi-Shiyambade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R and Zinsmeister AR: Gastroenterology 139: 1549-1558, 2010.

29. Camilleri M: Bile acid diarrhea: Prevalence, pathogenesis, and therapy. Gut Liver 9: 332-339, 2015.

30. Yueh TP, Chen FY, Lin TE and Chuang MT: Diarrhea after laparoscopic cholecystectomy: Associated factors and predictors. Asian J Surg 37: 171-177, 2014.

31. Hutccheon DF, Bayless TM and Gadacz TR: Postcholecystectomy diarrhea. JAMA 241: 823-824, 1979.

32. Fisher M, Spilias DC and Tong LK: Diarrhoea after laparoscopic cholecystectomy: Incidence and main determinants. ANZ J Surg 78: 482-486, 2008.

33. Middelfart HV, Kristensen JU, Laursen CN, Qvist N, Hoigaard L, Funch-Jensen P and Kehlet H: Pain and dyspepsia after elective and acute cholecystectomy. Scand J Gastroenterol 33: 10-14, 1998.

34. Lublin M, Crawford DL, Hiatt JR and Phillips EH: Symptoms before and after laparoscopic cholecystectomy for gallstones. Am Surg 70: 863-866, 2004.

35. Weinert CR, Arnett D, Jacobs D Jr and Kane RL: Relationship between persistence of abdominal symptoms and successful outcome after cholecystectomy. Arch Intern Med 160: 989-995, 2000.

36. Niranjani B, Chamber S and Kriplani AK: Symptomatic outcome after laparoscopic cholecystectomy. Trop Gastroenterol 21: 144-148, 2000.

37. Lamberts MP, Lugtenberg M, Rovers MM, Roukema AJ, Drenth JP, Westert GP and van Laarhoven CJ: Persistent and de novo symptoms after cholecystectomy: A systematic review of cholecystectomy effectiveness. Surg Endosc 27: 709-718, 2013.

38. Scarpetta G, Farno A, Mazzoni M and Malaguti P: Post-cholecystectomy diarrhea: evidence of bile acid malabsorption assessed by SeHCAT test. Am J Gastroenterol 87: 1852-1854, 1992.

39. Mearin F, De Ribot X, Balboa A, Antolin M, Varas MJ and Malagalda JR: Duodenogastric bile reflux and gastrointestinal motility in pathogenesis of functional dyspepsia. Role of cholecystectomy. Dig Dis Sci 40: 1703-1709, 1995.

40. Monaco L, Brillantino A, Torelli F, Schettino M, Izzo G, Cosenza A and Di Martino N: Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors. World J Gastroenterol 15: 334-338, 2009.

41. Bollschiweiler E, Wulfarten E, Pütz B, Gutschow C and Hüschter AH: Bile reflux into the stomach and the esophagus for volunteers older than 40 years. Digestion 71: 65-71, 2005.

42. McCabe ME IV and Dilly CK: New causes for the old problem of bile reflux gastritis. Clin Gastroenterol Hepatol 16: 1389-1392, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.